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In Brief
Li et al. show that primary
hyperparathyroidism in humans and PTH
treatment in mice induce bone loss by
increasing production of the
inflammatory cytokine IL-17A. Targeting
the IL-17 pathway, including treatment
with the prescription calcium channel
blocker drug, diltiazem, in mice prevents
cPTH-induced bone loss, suggesting new
treatment avenues.
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Primary hyperparathyroidism (PHPT) is a common
cause of bone loss that is modeled by continuous
PTH (cPTH) infusion. Here we show that the inflam-
matory cytokine IL-17A is upregulated by PHPT in
humans and cPTH in mice. In humans, IL-17A is
normalized by parathyroidectomy. Inmice, treatment
with anti-IL-17A antibody and silencing of IL-17A
receptor IL-17RA prevent cPTH-induced osteocytic
and osteoblastic RANKL production and bone
loss. Mechanistically, cPTH stimulates conventional
T cell production of TNFa (TNF), which increases
the differentiation of IL-17A-producing Th17 cells
via TNF receptor 1 (TNFR1) signaling in CD4+ cells.
Moreover, cPTH enhances the sensitivity of naive
CD4+ cells to TNF via GaS/cAMP/Ca2+ signaling.
Accordingly, conditional deletionofGaS inCD4+cells
and treatment with the calcium channel blocker dilti-
azemprevents Th17 cell expansionandblocks cPTH-
induced bone loss. Neutralization of IL-17A and
calcium channel blockers may thus represent novel
therapeutic strategies for hyperparathyroidism.
INTRODUCTION
Parathyroid hormone (PTH) is a major regulator of calciummeta-
bolism and bone homeostasis. PHPT, a condition characterized
by chronic overproduction of PTH, is a common cause of osteo-
porosis (Parisien et al., 2001; Potts, 1998; Silverberg et al., 1989)
that is modeled in animals by continuous PTH (cPTH) infusion.
Both PHPT and cPTH treatment stimulate bone resorption and,
to a lesser extent, bone formation (Qin et al., 2004), causing
cortical bone loss and often trabecular bone loss (Iida-Klein
et al., 2005; Potts, 1998).
The effects of cPTH on bone result from its binding to the PTH/
PTH-related protein (PTHrP) receptor (PPR or PTHR1), which is
expressed on bone marrow (BM) stromal cells, osteoblasts, andCell Mosteocytes (Calvi et al., 2001; Saini et al., 2013), but also T cells
(Terauchi et al., 2009) and macrophages (Cho et al., 2014). Early
consensus held that the catabolic effect of cPTH is mediated by
altered production of RANKL and OPG by stromal cells and oste-
oblasts (Maetal., 2001).Osteocyteshavenowemergedasessen-
tial targets of PTH, as osteocyte-produced RANKL is pivotal for
cPTH-induced bone loss (Ben-awadh et al., 2014; Saini et al.,
2013; Xiong et al., 2014). cPTH fails to induce bone loss in T cell
null mice and mice with conditional deletion of PPR in T cells
(Gao et al., 2008; Tawfeek et al., 2010), thus revealing that
T cells contribute to the mechanism of action of PTH in bone.
PPR activation in T cells stimulates TNF production by BM con-
ventional CD4+ and CD8+ cells (Tawfeek et al., 2010), and cPTH
fails to induce bone loss in mice specifically lacking TNF produc-
tion by T cells (Tawfeek et al., 2010). TNF upregulates CD40
expression in SCs, allowing T cell-expressed CD40L to regulate
the responsiveness of SCs to cPTH (Gao et al., 2008). However,
TNF is likely to contribute to the bone catabolic activity of cPTH
via additional effects. Moreover, the mechanisms by which
cPTH regulates T cell function, the specific population of T cells
that mediate the activity of cPTH, and the role of T cells in the ac-
tivity of PTH in humans remain to be determined.
Th17 cells are an osteoclastogenic population of CD4+ cells
(Miossec et al., 2009; Sato et al., 2006) defined by the capacity
to produce IL-17A and other minor members of the IL-17 family
of cytokines (Basuet al., 2013). Th17cells reside in theBM (Kappel
et al., 2009) and play a pathogenic role in inflammatory conditions
such as psoriasis, rheumatoid arthritis, multiple sclerosis, and
Crohn’sdisease (Martinezet al., 2008;Miossecetal., 2009).More-
over, Th17 cells contribute to the bone wasting caused by estro-
gen deficiency in mice (DeSelm et al., 2012; Tyagi et al., 2012)
and humans (Molna´r et al., 2014; Zhang et al., 2015). Th17 cells
potently induce osteoclastogenesis by secreting IL-17A, RANKL,
TNF, IL-1, and IL-6, alongwith low levels of IFNg (Jovanovic et al.,
1998; Komatsu and Takayanagi, 2012; Waisman, 2011). IL-17A
stimulates the release of RANKL by all osteoblastic cells including
osteocytes (Komatsu and Takayanagi, 2012; Kotake et al., 1999;
Sato et al., 2006) and potentiates the osteoclastogenic activity of
RANKL by upregulating RANK (Adamopoulos et al., 2010).
cPTH stimulates bone and immune cells to release growth fac-
tors and cytokines. Among them are TGFb, IL-6, and TNF (Kohetabolism 22, 799–810, November 3, 2015 ª2015 Elsevier Inc. 799
Table 1. Demographic and Clinical Data of Healthy Controls and
PHPT Patients Before and After Surgery
Healthy
Controls
PHPT Before
Surgery
PHPT After
Surgery
Study participants (n) 57 20 20
Age (years) 60.1 ± 2.3 57.3 ± 3.4a 57.3 ± 3.4a
Males (n) 25 4 4
Male age (years) 66.5 ± 3.6 67.5 ± 7.2a 67.5 ± 7.2a
Females (n) 32 16 16
Female age (years) 56.7 ± 2.9 54.5 ± 3.7a 54.5 ± 3.7a
Postmenopausal females (n) 23 8a 8a
Years since menopause 15.5 ± 2.3 15.7 ± 3.5a 15.7 ± 3.5a
Serum Ca (mg/dl)
(8.8–10.4 mg/dl)
9.4
(9.1–9.7)
10.8
(10.5–12.0)b
8.8
(8.7–9.1)b,d
Serum P (mg/dl)
(2.5–4.5 mg/dl)
3.3 ± 0.07 2.7 ± 0.3c 3.5 ± 0.4a,e
PTH (pg/ml) (10–65 pg/ml) 53
(32–63)
102
(79–161)b
56.5
(41.8–75.8)a,d
25OH vitamin D
(30–100 ng/ml)
19.6
(5.7–27.2)
17.8
(15.1–22.4)a
23.6
(21.9–30.4)a,f
Data are shown as mean ± SEM for normally distributed variables (serum
P and demographic data) and median with interquartile range for non-
normally distributed variables (serum Ca, PTH, and 25OH vitamin D).
Values in parentheses following the variables denote normal range.
ap = ns compared to healthy controls.
bp = < 0.0001 compared to healthy controls.
cp = 0.005 compared to healthy controls.
dp = < 0.0001 compared to PHPT.
ep < 0.05 compared to PHPT.
fp < 0.01 compared to PHPT.
Figure 1. Primary Hyperparathyroidism Increases IL-17A and RORC
mRNA Levels in Humans
(A and B) Levels (median ± interquartile range) of IL-17A and RORC mRNAs in
healthy controls (n = 57) and subjects with PHPT before (n = 20) and after
parathyroidectomy (n = 20). Data were analyzed by Mann-Whitney (healthy
controls versus PHPT before surgery and healthy controls versus PHPT after
surgery) and Wilcoxon matched-pairs signed-rank tests (PHPT versus PHPT
after surgery) as the data were not normally distributed according to the
Shapiro-Wilk normality test.et al., 2011; Lo¨wik et al., 1989; Tawfeek et al., 2010), factors that
direct the differentiation of naive CD4+ cells into Th17 cells (Basu
et al., 2013; Bettelli et al., 2006; Nakae et al., 2007; Sugita et al.,
2012). Therefore, it is plausible that cPTH may induce Th17 cell
differentiation in the BM and that IL-17A produced by BM Th17
cells may act as an upstream cytokine that plays a pivotal role
in the bone loss induced by cPTH and PHPT.
This study was designed to determine the effects of PHPT and
cPTH on the production of IL-17A in humans and mice and to
investigate the contribution of IL-17A to the bone loss induced
by cPTH in mice. We report that PHPT increases peripheral
blood cell expression of IL-17A mRNA, which is normalized by
parathyroidectomy. We also show that in mice, cPTH promotes
Th17 cell differentiation via TNFR1 signaling in T cells. In addi-
tion, cPTH enhances the sensitivity of naive CD4+ cells to TNF
via the GaS/cAMP/Ca2+ signaling pathway. Attesting to rele-
vance of IL-17A and PTH signaling in T cells, silencing of IL-
17RA or GaS and treatment with neutralizing anti IL-17A anti-
body or the calcium channel blocker diltiazem prevent cPTH-
induced bone loss.
RESULTS AND DISCUSSION
Increased Production of IL-17A in Humans Affected
by PHPT
To investigate the effects of PHPT on the production of cyto-
kines, unfractionated peripheral blood nucleated cells were ob-800 Cell Metabolism 22, 799–810, November 3, 2015 ª2015 Elseviertained from 57 healthy controls and 20 subjects affected by
PHPT of similar gender, age, and years since menopause.
The demographic characteristics of the study population and
the serum levels of calcium, phosphorous, PTH, and 25-hy-
droxy vitamin D are shown in Table 1. In PHPT patients, blood
samples were obtained before surgery and 1 month after suc-
cessful resolution of PHPT by parathyroidectomy. Overproduc-
tion of IL-17A has been documented in inflammatory conditions
associated with local and systemic bone loss such as psoriasis,
rheumatoid arthritis, and Crohn’s disease (Martinez et al., 2008;
Miossec et al., 2009), but the effects of PHPT on IL-17A are un-
known. Analysis by real-time RT-PCR revealed that the mRNA
levels of IL-17A in unfractionated peripheral blood nucleated
cells were 3-fold higher in PHPT patients than in healthy
controls (Figure 1A). Moreover, surgical restoration of normal
parathyroid function was associated with the normalization of
IL-17A levels, as demonstrated by the finding at 1 month
after parathyroidectomy of similar IL-17A mRNA levels in
healthy subjects and former PHPT patients. Furthermore, the
mRNA levels of the IL-17-inducing transcription factor RORC
were 3-fold higher in PHPT patients before surgery than in
healthy controls (Figure 1B), and parathyroidectomy was fol-
lowed by a decrease in RORC mRNA levels. As a result, levels
of RORC mRNA in healthy controls and PHPT patients afterInc.
Figure 2. cPTH Treatment Expands Th17
Cells and Increases L-17A Production
(A–C) Frequency of IL-17A-producing Th17 cells in
unfractionated peripheral blood (PB) cells (PBC).
(A) shows representative flow cytometric dot plots
from one mouse per group. (B) shows the relative
frequency of CD4+IL-17A+ PBC. Data are ex-
pressed as % of CD4+ cells. (C) shows the abso-
lute number of CD4+IL-17A+ PBCs per sample.
(D) IL-17A mRNA levels in PB CD4+ cells.
(E) IL-17A mRNA levels in unfractionated PBC and
CD4+ cell-depleted PBC.
(F) Relative frequency of Th17 cells in the BM.
(G) Absolute number of BM Th17 cells per sample.
(H) IL-17A mRNA levels in BM CD4+ cells.
(I) IL-17A protein levels in BM CD4+ cells.
(J) mRNA levels of the Th17 cells-inducing tran-
scription factors RORa and RORgt in BM CD4+
cells.
(K) Relative frequency of Th17 cells in the spleen.
(L) Absolute number of Th17 cells in the spleen.
(M) IL-17A mRNA levels in spleen CD4+ cells.
Data in (B)–(M) are shown as mean ± SEM n = 8
mice per group in all panels. All data passed the
Shapiro-Wilk normality test and were analyzed by
unpaired t tests. ** = p < 0.01 and *** = p < 0.001
compared to the corresponding vehicle group.surgery were not significantly different. Whether PHPT in-
creases levels of IL-17A protein in the peripheral circulation
and in the BM remains to be determined.
In the entire study population PTH levels were directly corre-
lated with mRNA levels of IL-17A (r = 0.38, p < 0.005) and
RORC (r = 0.27, p < 0.05). Moreover, disease status (healthy or
PHPT) and age were independent predictors of IL-17A and
RORC mRNA levels, whereas gender was not (Tables S1 and
S2). These differences in IL-17A and RORC levels between
healthy controls and PHPT patients remained significant even
after adjustment for age and gender by a multiple regression
model.
These findings suggest that increased IL-17A gene expression
in PHPT patients is due to increased levels of circulating PTH.
However, we cannot exclude the possibility that IL-17A might
be regulated by factors modified by PTH, such as serum levels
of calcium, phosphate, and calcitriol. A previous cross-sectional
study in patients on dialysis with hyperparathyroidism secondaryCell Metabolism 22, 799–810,to end-stage renal disease revealed a
direct correlation between phosphate
levels and frequency of peripheral blood
Th17 cells (Lang et al., 2014). By contrast,
in our study IL-17A levels were increased
in PHPT patients who have decreased
phosphate levels. Moreover, we found
no correlation between IL-17A and
RORC expression and serum phosphate
levels.
PHPT was also associated with
increased mRNA levels of TNF and IL-
23, which were normalized by parathy-
roidectomy. By contrast all groups had
similar mRNA levels of IFNg and IL-4,suggesting that PHPT does not expand Th1 cells or Th2 cells
(Figure S1).
Treatment with cPTH Expands Th17 Cells and IL-17A
Production in the Mouse
To investigate the effect of PTH in mice, human PTH1-34
was continuously infused at the rate of 80 mg/kg/day for
2 weeks, a treatment modality referred to hereafter as
cPTH. Analysis by flow cytometry of unfractionated periph-
eral blood nucleated cells harvested at sacrifice revealed
that cPTH increased the relative and absolute frequency
of peripheral blood Th17+ cells (Figures 2A–2C). Moreover,
cPTH increased IL-17A mRNA levels in purified peripheral
blood CD4+ cells (Figure 2D) and unfractionated peripheral
blood nucleated cells, but not in CD4+ cell-depleted periph-
eral blood nucleated cells (Figure 2E), indicating that CD4+
cells represent the major source of IL-17 mRNA in peripheral
blood cells.November 3, 2015 ª2015 Elsevier Inc. 801
Mirroring its activity in peripheral blood, cPTH increased by
2-fold the relative and absolute frequency of Th17 cells in the
BM (Figures 2F and 2G), by 5-fold the levels of IL-17A mRNA
in purified BM CD4+ cells (Figure 2H), and by 2-fold the levels
of IL-17Aprotein in the culturemedia of BMCD4+ cells (Figure 2I).
Moreover, cPTH increased the expression of the Th17-inducing
transcription factors RORa and RORgt in BM CD4+ T cells (Fig-
ure 2J). cPTH treatment was also associated with a 2-fold in-
crease in the relative and absolute frequency of splenic Th17
cells (Figures 2K and 2L) and a 4-fold increase in the levels of
IL-17A mRNA in purified splenic CD4+ cells (Figure 2M). By
contrast, cPTH did not increase the relative and absolute fre-
quency of IFNg+CD4+ cells, IL-4+CD4+ cells, and FoxP3+CD4+
cells in the peripheral blood, BM, and spleen (Figure S2), indi-
cating that cPTH does not expand murine Th1 cells, Th2 cells,
and regulatory T cells.
Although IL-17A is mostly produced by Th17 cells, it can also
be produced by gd T cells, innate lymphoid cells, NK cells, NKT
cells, neutrophils, and eosinophils (Korn et al., 2009; Lockhart
et al., 2006; Sutton et al., 2009). Our data do not support a role
for gd T cell-produced IL-17A in the bone catabolic activity of
cPTH because TCRb/ mice, a strain lacking ab but not gd
T cells, are completely protected against cPTH-induced bone
loss (Gao et al., 2008).
Neutralization of IL-17A or Silencing of IL-17RA Blocks
cPTH-Induced Bone Loss
To investigate whether IL-17A contributes to the bone catabolic
activity of cPTH, WTmice were treated with vehicle or cPTH and
either a neutralizing antibody directed against murine IL-17A (IL-
17A Ab) or isotype-matched irrelevant Ab (Irr. Ab) at the dose of
2.5mg/kg, twice per week, for 2weeks. To assess the differential
effects of cPTH on cortical and trabecular bone, micro-
computed tomography (mCT) was utilized to analyze femurs har-
vested at sacrifice. cPTH induced significant loss of cortical
thickness (Ct.Th) and volume (Ct.Vo) and trabecular bone vol-
ume (BV/TV) in mice treated with Irr. Ab, but not in those treated
with IL-17A Ab (Figure 3A). Analysis of indices of trabecular
structure revealed that cPTH had opposite effects in trabecular
number (Tb.N) in mice treated with Irr. Ab and those treated
with IL-17A Ab. A similar trend was observed for trabecular
space (Tb.Sp). By contrast, cPTH induced decreased trabecular
thickness (Tb.Th) in all mice (Figures S3A–S3C).
Analysis of femoral cancellous bone by histomorphometry re-
vealed that neutralization of IL-17A blunts the bone catabolic
activity of cPTH by decreasing bone resorption. In fact, cPTH
treatment increased two indices of bone resorption, the number
of OCs per bone surface (N.Oc/BS) and the percentage of sur-
faces covered by OCs (Oc.S/BS), in mice treated with Irr. Ab
but not in those treated with IL-17Ab (Figure 3B). Analysis of dy-
namic indices of bone formation revealed that cPTH increased
mineral apposition rate (MAR) and bone formation rate (BFR) in
mice treated with Irr. Ab and in those treated with IL-17A Ab (Fig-
ure 3C). Two static indices of bone formation, the number of OBs
per bone surface (N.Ob/BS) and the percentage of surfaces
covered by OBs (Ob.S/BS) increased significantly in response
to treatment with cPTH in both mice treated with Irr. Ab and
those treated with IL-17A Ab (Figure 3C). These indices were un-
expectedly higher in the vehicle/IL-17A Ab group as compared802 Cell Metabolism 22, 799–810, November 3, 2015 ª2015 Elsevierto the vehicle/Irr. Ab group. Confirmation that neutralization of
IL-17A blunts the bone catabolic activity of cPTH by decreasing
bone resorption was provided by measurements of serum levels
of C-terminal telopeptide of collagen (CTX), a marker of bone
resorption, and total procollagen type 1 N-terminal propeptide
(P1NP), a marker of bone formation. These assays revealed
that treatment with IL-17A Ab significantly blunted the increase
in serum CTX levels induced by cPTH, while it did not diminish
the cPTH-induced increase in P1NP levels (Figure 3D).
The blockade of bone resorption induced by IL-17 Ab was of
greater magnitude when estimated by serum levels of CTX
than when measured by bone histomorphometry. The likely
explanation for this phenomenon is that CTX levels reflect both
cortical and trabecular bone resorption while histomorphometric
indices were calculated only in the trabecular compartment. This
is relevant because cortical bone accounts for most of the total
bone mass and cPTH affects primarily the cortical compartment
of the skeleton.
In summary, the data demonstrate that neutralization of IL-17A
blunts the capacity of cPTH to stimulate bone resorption without
affecting bone formation. These changes in bone turnover pre-
vented bone loss, but did not cause a significant increase in
bone volume, presumably because of the short duration of the
IL-17Ab treatment.
Osteocytes and the pool of RANKL produced by osteocytes
are crucial for the activity of cPTH. In fact, not only does silencing
of PPR expression in osteocytes blunt the bone catabolic activity
of cPTH (Saini et al., 2013), but increased production of RANKL
by osteocytes is now known to play a pivotal role in cPTH-
induced bone loss (Ben-awadh et al., 2014; Saini et al., 2013;
Xiong et al., 2014). Reports from our laboratory have led to the
hypothesis that T cells are also an important target of PTH (Pacif-
ici, 2013), primarily because silencing of PPR in T cells protects
against cPTH-induced bone loss (Tawfeek et al., 2010). The fact
that silencing of PPR signaling in T cells and osteocytes induces
similar bone sparing effects is in keeping with a ‘‘serial circuit’’
regulatory model, where signals from one population affect the
response to cPTH of the other. Since T cells and osteocytes
have limited physical contacts, the crosstalk between these
populations is likely mediated by a soluble factor. IL-17A is a
likely candidate because it is a potent inducer of RANKL in organ
cultures containing osteoblasts and osteocytes (Nakashima
et al., 2000). In support of this hypothesis, we found IL-17A Ab
to completely block the increase in osteocytic RANKL mRNA
levels induced by cPTH (Figure 3E). Further attesting to a causal
role of IL-17A, we found that treatment with IL-17A Ab
completely blocked the capacity of cPTH treatment to increase
the expression of RANKL, TNF, IL-1b, and IL-6mRNAs in purified
osteoblasts, and the increase in the expression of TNF mRNA in
purified BM T cells (Figure S4A). These data indicate that IL-17A
maymediate the bone catabolic activity of cPTH by upregulating
the production of RANKL by osteocytes and osteoblasts.
IL-17A binds to the heterodimeric receptor IL-17RA/IL-17RC,
known as IL-17RA (Iwakura et al., 2011; Zepp et al., 2011). IL-
17A signaling is silenced in IL-17RA/ mice (Ye et al., 2001).
We made use of IL-17RA/ mice to further investigate whether
IL-17A contributes to the bone catabolic activity of cPTH.
Sixteen-week-old IL-17RA/ mice and WT littermates were
treated with vehicle or cPTH for 2 weeks. In vitro mCT analysisInc.
Figure 3. Silencing of IL-17A or IL-17A
Signaling Prevents the Bone Catabolic Ef-
fect of cPTH
(A–H) Effects (mean ± SEM) of cPTH on bone
volume, structure, and turnover in mice treated
with IL-17A Ab or lacking IL-17RA.
(A) In vitro measurements of cortical and trabec-
ular bone indices of volume and structure by mCT
scanning in WT mice treated with vehicle or cPTH
and Irrelevant Ab (Irr. Ab) or anti IL-17A Ab. n = 12
mice per group. Representative three-dimensional
mCT reconstructions of the femurs are shown
above the data.
(B) Histomorphometric indices of bone resorption
(obtained in the first 10 of the 12 mice per group
enrolled in the study). The images show TRAP-
stained sections of the distal femur used to
compute the number of OCs per mm bone surface
(N.Oc/BS) and the percentage of bone surface
covered by OCs (Oc.S/BS), which are indices of
bone resorption. Original magnification 403.
(C) Dynamic indices of bone formation. The im-
ages show calcein double-fluorescence labeling
used to compute mineral apposition rate (MAR)
and bone formation rate (BFR), which are indices
of bone formation. Original magnification 203. The
number of OBs per mm bone surface (N.Ob/BS)
and the percentage of bone surface covered by
OBs (Ob.S/BS), which are static indices of for-
mation, were measured on trichrome-stained
sections.
(D) Serum levels of CTX and P1NP. n = 12mice per
group.
(E) mRNA levels of RANKL in enriched osteocytes.
n = 5 mice per group.
(F) mCT measurements of cortical and trabecular
bone volume and structure in samples from WT
and IL-17RA/ mice. n = 14 mice per group. The
images are three-dimensional reconstructions of
the femurs.
(G) Serum levels of CTX and P1NP. n = 14mice per
group.
(H) mRNA levels of RANKL in enriched osteocytes
fromWTand IL-17RA/mice.n=5micepergroup.
All data passed the Shapiro-Wilk normality test and
were analyzed by two-way ANOVA. * = p < 0.05,
** = p < 0.01, and *** = p < 0.001 compared to the corresponding vehicle treated group. # = p < 0.05 and ## = p < 0.01 compared to IL-17 Ab cPTH. ### = p <
0.001 compared to IL-17RA/ cPTH. a = p < 0.05 compared to Irr. Ab Veh. b = p < 0.05 compared to WT Veh.of femurs harvested at sacrifice revealed that cPTH induced sig-
nificant losses of Ct.Th, Ct.Vo, and BV/TV in WT mice but not in
IL-17RA/ mice (Figure 3F). For reasons that remain undeter-
mined, Ct.Th was lower in vehicle-treated IL-17RA/ mice as
compared to vehicle-treated WT mice. Parameters of trabecular
structure (Tb.N, Tb.Th, and Tb.Sp) were altered by cPTH in WT
but not in IL-17RA/ mice (Figures S3D–S3F).
Serum CTX levels were increased by cPTH in WT but not in IL-
17RA/mice (Figure 3G). By contrast, serum P1NP levels were
increased by cPTH in WT and IL-17RA/ mice (Figure 3G). Os-
teocytic RANKL mRNA levels were increased by cPTH in WT but
not in IL-17RA/ mice (Figure 3H). Finally, cPTH treatment
increased the osteoblastic expression of RANKL, TNF, IL-1b,
and IL-6 mRNAs and the T cell expression of TNF mRNA in in
WT but not IL-17RA/ mice (Figure S4B). These findings
demonstrate that silencing of IL-17RA prevents the loss ofCell Mcortical and trabecular bone and the increase in bone resorption
and the osteoblastic/osteocytic RANKL production induced by
cPTH. Importantly, the data confirm that IL-17A acts as an up-
stream cytokine that drives bone loss by increasing the sensi-
tivity of osteoblasts and osteocytes to cPTH, thus enabling these
lineages to release RANKL when stimulated by cPTH. Parallel
deletions of PPR in T cells, osteocytes, and osteoblasts as well
as conditional deletion of IL-17RA in osteocytes and osteoblasts
will be necessary to conclusively confirm this hypothesis.
cPTH Increases the Differentiation of Th17Cells via TNF
and GaS Signaling
IL-6 and TGFb initiate Th17 differentiation (Basu et al., 2013;
Martinez et al., 2008) while TNF, IL-1, and IL-23 amplify it (Veld-
hoen et al., 2006). The relevance of TNF for Th17 cell expansion
has emerged by investigations on the effects of TNF blockers,etabolism 22, 799–810, November 3, 2015 ª2015 Elsevier Inc. 803
Figure 4. cPTH Expands Th17 Cells through
TNF and TNFR1 Signaling
(A and B) Relative frequency of Th17 cells in the
spleen and BM of WT and TNF/ mice.
(C) IL-17A mRNA levels in BM CD4+ cells of WT
and TNF/ mice.
(D and E) RORa and RORgt mRNA levels in BM
CD4+ cells of WT and TNF/ mice.
(F) Relative frequency of Th17 cells in the BM of
TCRb/ mice previously subjected to adoptive
transfer of WT T cells, TNF/ T cells, TNFR1/
T cells, or TNFR2/ T cells.
(G) IL-17A mRNA levels in BM CD4+ cells of
TCRb/ mice previously subjected to adoptive
transfer of WT T cells, TNF/ T cells, TNFR1/
T cells, or TNFR2/ T cells.
(H and I) Levels of RORa and RORgt mRNA in BM
CD4+ cells of TCRb/ mice previously subjected
to adoptive transfer of WT T cells, TNF/ T cells,
TNFR1/ T cells, or TNFR2/ T cells.
Data are expressed as themean ± SEM. n = 8mice
per group. All data passed the Shapiro-Wilk
normality test and were analyzed by two-way
ANOVA.* = p < 0.05, ** = p < 0.01, and *** = p <
0.001 compared to the corresponding vehicle
group.which have demonstrated that TNF contributes to the expansion
of Th17 cells in inflammatory conditions in humans and rodents
(Nakae et al., 2007; Sugita et al., 2012). Accumulation of cAMP in
CD4+ cells and the resulting Ca2+ influx further promote Th17 cell
differentiation and activity (Li et al., 2012). Treatment with cPTH
induces the production of IL-6 and TGFb by bone and immune
cells (Koh et al., 2011; Lo¨wik et al., 1989) and the release of
TNF by BM CD4+ and CD8+ cells (Tawfeek et al., 2010). PTH
binding to PPR activates the G protein-coupled receptor subunit
GaS, leading to the generation of cAMP (Datta and Abou-Samra,
2009). Therefore, several mechanisms could account for the ca-
pacity of cPTH to expand Th17 cells.
We utilized BM cells, which are essential for the regulation of
bone homeostasis, and cells from the spleen, an organ not
known to regulate bone remodeling, to determine the mecha-
nism by which cPTH expands Th17 cells. BrdU incorporation
studies revealed that cPTH did not increase the proliferation of
Th17 cells in the BM and the spleen (Figures S5A and S5B). IL-
17A-eGFP mice were utilized to investigate the differentiation804 Cell Metabolism 22, 799–810, November 3, 2015 ª2015 Elsevier Inc.of naive CD4+ cells into Th17 cells. IL-
17A-eGFP reporter mice possess an
IRES-eGFP sequence after the stop
codon of the IL17A gene so that eGFP
expression is limited to IL-17A-express-
ing cells, allowing Th17 cells to be
detected by measuring eGFP by flow
cytometry. Splenic naive CD4+ cells
(CD4+CD44loCD62LhieGFP cells) were
FACS sorted from IL-17A-eGFP mice
and transferred into congenic T cell-defi-
cient TCRb/mice. Recipient mice were
treated with vehicle or cPTH for 2 weeks
starting 2 weeks after the T cell transfer,and newly produced Th17 cells (CD4+eGFP+ cells) were
counted. Since TCRb/ mice were reconstituted with eGFP
cells, the number of eGFP+ cells in host mice at sacrifice pro-
vides a direct quantification of the differentiation of naive CD4+
cells into Th17 cells. cPTH-treated mice had a higher number
eGFP+ cells than controls in the BM and the spleen (Figures
S5C and S5D), demonstrating that cPTH increases Th17 cell dif-
ferentiation in the BM and the spleen.
TNF expands Th17 cells and mediates the catabolic activity of
cPTH (Chen et al., 2011; Nakae et al., 2007; Sugita et al., 2012).
Therefore, we investigated the overall contribution of TNF and
the specific role of T cell-produced TNF in the expansion of
Th17 cells induced by cPTH. WT and TNF/ mice were treated
with cPTH for 2 weeks and the relative frequency of BM Th17
cells determined. cPTH increased the frequency of Th17 cells
in the spleen and the BM inWTmice, but not in TNF/mice (Fig-
ures 4A and 4B). Analysis of purified BMCD4+ cells revealed that
cPTH increased IL-17AmRNA levels (Figure 4C) and the expres-
sion of RORa and RORgt (Figures 4D and 4E) in BM CD4+ cells
fromWT but not in those from TNF/mice. Thus, cPTH induces
Th17 cells via TNF. Next, splenic T cells from WT and TNF/
mice were transferred into TCRb/ mice. Recipient mice were
treated with vehicle or cPTH for 2 weeks starting 2 weeks after
the T cell transfer. cPTH increased the number of Th17 cells (Fig-
ure 4F), IL-17A mRNA levels in CD4+ cells (Figure 4G), and the
expression of RORa and RORgt in CD4+ cells (Figures 4H and
4I) in the BM of host mice with WT T cells but not in those with
TNF/ T cells. These findings demonstrate that the production
of TNF by T cells is required for cPTH to expand Th17 cells.
To determine whether TNF directly targets Th17 precursors,
splenic CD4+ cells from TNFR1/ and TNFR2/ mice were
transferred into TCRb/ mice. Host mice were treated with
vehicle or cPTH for 2 weeks starting 2 weeks after the T cell
transfer. cPTH expanded BM Th17 cells in mice with TNFR2/
T cells, but not in those with TNFR1/ T cells (Figure 4F). More-
over, cPTH increased IL-17AmRNA levels in BMCD4+ cells (Fig-
ure 4G) and the BM CD4+ cell expression of RORa and RORgt
(Figures 4H and 4I) in mice with TNFR2/ T cells but not in those
with TNFR1/ T cells. These findings demonstrate that cPTH
expands the pool of BM Th17 cells through direct TNFR1
signaling in T cells.
In addition to TNF, several cytokines are known to promote
Th17 cell expansion. Among them are the T cell-produced factor
IL-21 and the macrophage/dendritic cell-produced cytokine IL-
23. We found that cPTH treatment increased the mRNA levels
of IL-21 and IL-23R in BM and spleen CD4+ cells from WT but
not TNF/ mice (Figures S6A and S6B). Moreover, cPTH
increased the mRNA levels of IL-23 in BM CD11c+ cells from
WT but not TNF/ mice (Figure S6C). These findings suggest
that IL-21 and IL-23 may contribute to expansion of Th17 cells
induced by cPTH. However, cPTH upregulates these factors
via TNF.
In summary, our human and murine data indicate that TNF
acts directly by upregulating the Th17-inducing factors IL-21
and IL-23. However, our findings do not exclude the possibility
that PTH-mediated stimulation of IL-6 and TGFb production
may contribute to the expansion of Th17 cells induced by cPTH.
Conditional deletion of the G protein-coupled receptor subunit
GaS in T cells impairs the generation of Th17 cells (Li et al., 2012).
Since PTH binding to PPR activates GaS (Datta and Abou-
Samra, 2009), cPTH could further upregulate Th17 differentiation
by activating GaS in naive CD4+ T cells. To investigate the role
of GaS, we generated GaSDCD4,8 mice by crossing C57BL/6
GaS fl/fl mice with C57BL/6 CD4-Cre mice, as previously
described (Li et al., 2012). The targeted genetic deletion of
GaS with CD4-Cre occurs at the CD4+CD8+ double-positive
stage of T cell development (Li et al., 2012). Consequently,
both CD4+ and CD8+ T cells from GaSDCD4,8 mice lack GaS
expression. GaSDCD4,8, Gas fl/fl, and WT mice have similar
numbers of CD4+ and CD8+ cells, and similar percentages of
effector, memory, and naive CD4+ andCD8+ cells (Li et al., 2012).
One mechanism by which activation of GaS in CD4+ cells
could promote Th17 cell differentiation is increased sensitivity
to TNF. To investigate this hypothesis, naive splenic CD4+ cells
from vehicle- and cPTH-treated WT, GaS fl/fl, and GaSDCD4,8
mice were cultured in vitro in anti-CD3 Ab- and anti-CD28-
coated wells for 3 days in the presence of TNF at 10–50 ng/ml
to induce the conversion of CD4+ cells into Th17 cells. CulturesCell Mof CD4+ cells from cPTH-treated WT and GaS fl/fl mice yielded
a higher number of Th17 cells as compared to those from
vehicle-treated mice (Figure 5A). By contrast, cultures of CD4+
cells from vehicle- and cPTH-treated GaSDCD4,8 mice yielded
similar numbers of Th17 cells, demonstrating that cPTH in-
creases the sensitivity of nascent Th17 cells to TNF via GaS
signaling in CD4+ cells. Mechanistic studies revealed that treat-
ment with cPTH for 2 weeks increased the mRNA levels of
TNFR1- and the TNFR1-activated signaling molecule TRAF2
(Qin et al., 2012) in BM CD4+ cells from of WT and Gas fl/fl
mice, but not in those from GaSDCD4,8 mice (Figures 5B and
5C) indicating that activation of GaS signaling by cPTH increases
the sensitivity of nascent Th17 cells to TNF by upregulating
TNFR1 expression and TNFR1 signaling.
Treatment of GaSDCD4,8 and Gas fl/fl control mice with cPTH
for 2 weeks increased the frequency of BM Th17 cells (Figure 5D)
and induced significant losses of Ct.Th, Ct.Vo, and BV/TV (Fig-
ures 5E–5G), and of Tb.Th (Figure S7A) in GaS fl/fl mice but
not GaSDCD4,8 mice. Unexpectedly, cPTH did not affect Tb.Sp
and Tb.N in all mice (Figures S7B and S7C). cPTH also increased
serum CTX levels in GaS fl/fl but not GaSDCD4,8 mice (Figure 5H).
Serum P1NP and osteocalcin (OCN) levels were increased by
cPTH in GaS fl/fl and GaSDCD4,8 mice (Figures 5I and 5J). These
findings demonstrate that silencing of Gas in T cells prevents the
expansion of Th17 cells, the loss of cortical and trabecular bone,
and the increase in bone resorption induced by cPTH.
Signaling events downstream of GaS include cAMP genera-
tion (Li et al., 2012) and activation of L-type calcium channels
(Hell, 2010). The latter contributes to Th17 cell differentiation
(Oh-hora, 2009). Accordingly, in vitro treatment with the L-type
calcium channel blocker diltiazem blunts the differentiation of
CD4+ cells into Th17 cells (Li et al., 2012). We fed mice with or
without diltiazem in their drinking water (Mieth et al., 2013; Sem-
sarian et al., 2002) and infused them with vehicle or cPTH. Dilti-
azem blocked the increase in the number of BM Th17 cells (Fig-
ure 6A), the BM mRNA levels of IL-17A (Figure 6B), and the BM
CD4+ cell expression of RORa and RORgt (Figures 6C and 6D)
induced by cPTH. Moreover, diltiazem completely blocked the
decrease in Ct.Vo, Ct.Th, and BV/TV induced by cPTH (Figures
6E–6G). It also altered the response of parameters of trabecular
structure to cPTH (Figures 6H–6J). Diltiazem blocked the in-
crease in serum CTX levels but not the increase in serum
P1NP induced by cPTH (Figures 6K and 6L). These data demon-
strate that diltiazem prevents the loss of cortical and trabecular
bone induced by cPTH by blunting bone resorption. The finding
that in vivo treatment with diltiazem blocks Th17 cell expansion
and prevents cPTH-induced bone loss may suggest a potential
therapeutic role for L-type calcium channel blockers in the treat-
ment of hyperparathyroidism, even though the available data do
not exclude the possibility of additional effects of diltiazem on
immune cells that may contribute to its bone sparing activity.
A striking and unexpected finding of this investigation is that
neutralization of IL-17A and deletion of IL-17RA block the capac-
ity of cPTH to increase the production of RANKL by osteocytes
and osteoblasts. These findings and the published literature sug-
gest that T cells, osteoblasts, and osteocytes are all required for
the high levels of PTH characteristic of PHPT to induce bone
loss. By contrast, osteocytes, but not T cells and IL-17A, are
required for physiologic levels of endogenous PTH to regulateetabolism 22, 799–810, November 3, 2015 ª2015 Elsevier Inc. 805
Figure 5. cPTH Expands Th17 Cells, Causes
Bone Loss, and StimulatesBoneResorption
through Activation of GaS in Naive CD4+
Cells
(A) cPTH increases the sensitivity to TNF of naive
CD4+ cells from WT and GaS fl/fl mice but not of
those fromGaSDCD4,8mice. Naive CD4+ cells were
sorted from vehicle- and cPTH-treated mice and
cultured with TNF (10–50 ng/ml) to induce their
differentiation into Th17 cells.
(B) TNFR1 mRNA levels in BM CD4+ cells.
(C) TRAF2 mRNA levels in BM CD4+ cells
(D) Frequency of BM Th17 cells.
(E–G) mCT indices of bone volume and structure.
(H–J) Serum levels of CTX, P1NP, and osteocalcin
(OCN).
Data are shown as mean ± SEM. n = 5 mice per
group for (B) and (C). n = 16 GaS fl/fl mice per
group and 21 GaSDCD4,8 mice per group for
(D)–(J). All data passed the Shapiro-Wilk
normality test and were analyzed by two-way
ANOVA. * = p < 0.05, ** = p < 0.01, *** = p < 0.001,
and **** = p < 0.0001 compared to the corre-
sponding vehicle group. # = p < 0.05 compared to
the GaSDCD4,8 cPTH group.bone remodeling. In fact, mice lacking PPR signaling in osteo-
cytes have high baseline bone volume (Saini et al., 2013), while
IL-17RA null mice and those lacking PPR signaling in T cells
(Bedi et al., 2012; Tawfeek et al., 2010) have a normal bone
volume.
Direct clinical applications of the current study arise because
L-type calcium channel blocker are available, while anti-human
IL-17A Abs and IL-17 receptor Abs are under investigation as
therapeutic agents in psoriasis and spondyloarthropathy (Leo-
nardi et al., 2012; Martin et al., 2013; Mease et al., 2014; Yer-
emenko et al., 2014). Therefore, our findings demonstrate a
novel role for IL-17A in the mechanism of action of cPTH and
provide a proof of principle for the use of L-type calcium
channel blocker and IL-17A Ab in the treatment of primary
hyperparathyroidism.EXPERIMENTAL PROCEDURES
Human Study Population
All human studies were approved by the Ethical Committee of the A.O.U. Citta`
della Salute e della Scienza (A.O. Ordine Mauriziano, A.S.L. TO1, Turin), and806 Cell Metabolism 22, 799–810, November 3, 2015 ª2015 Elsevier Inc.informed consent was obtained from all partici-
pants. The study population was recruited from
the patients of A.O.U. Citta` della Salute e della Sci-
enza and healthy volunteers. The study population
included 20 patients (16 women and 4 men)
affected by primary hyperparathyroidism (PHPT)
and 57 healthy subjects (25 males and 32 females)
comparable for age and years since menopause.
The demographic characteristics of the study
population are shown in Table 1. The diagnosis
of PHPT was established based on the finding of
elevated circulating levels of calcium and PTH in
at least two instances and the presence of normal
renal function. PHPT patients were subjected to
parathyroidectomy and restoration of normalparathyroid function was demonstrated by the finding of normal serum PTH
levels 1 month after surgery. Inclusion and exclusion criteria are provided in
Supplemental Experimental Procedures.
Measurements of IL-17A, TNFa, IL-23, IL-4, IFNg, and RORC mRNAs
in Human Samples
Red cells were lysed in all peripheral blood samples, and total nucleated cells
were collected and dissolved in TRIzol reagent (Ambion) and frozen at 80C
until RNA extraction. RNA was isolated using chloroform extraction, and sub-
sequent isopropanol precipitation according to the manufacturer’s protocol.
One microgram of RNAwas reverse-transcribed to cDNA using a High Capac-
ity cDNA Reverse Transcription Kit (Applied Biosystems). Real-time RT-PCR
was performed with IQ SYBR Green Supermix (Bio-Rad). Relative IL-17A,
RORC, IFNg, IL-4, IL-23, and TNFa gene expression was determined using
the 2DDCT method with normalization to b-actin. The primers used are listed
as Supplemental Information.
Animals
All the animal procedures were approved by the Institutional Animal Care and
Use Committee of Emory University. Female C57BL/6WT, TNF/, TNFR1/,
TNFR2/, TCRb/, and IL17A-GFP knockin (IL17atm1Bcgen/J) mice were pur-
chased from Jackson Laboratories. C57BL/6 IL-17RA/ were provided by
Amgen, Inc. C57BL/6 GaS fl/fl mice were provided by Dr. Lee Weinstein
(NIH). C57BL/6 CD4-Cre mice were purchased from Taconic. GaSDCD4,8
Figure 6. The L-Type Calcium Channel
Blocker Diltiazem Prevents the Effects of
cPTH
(A) Relative frequency of BM Th17 cells.
(B) IL-17A mRNA levels in BM CD4+ cells.
(C and D) Expression of RORa and RORgt mRNA
in BM CD4+ cells.
(E–J) mCT indices of bone volume and structure.
(K and L) Serum levels of CTX and P1NP.
Data are shown as mean ± SEM. n = 12 mice per
group. All data passed the Shapiro-Wilk nor-
mality test and were analyzed by two-way
ANOVA. * = p < 0.05, ** = p < 0.01, *** = p < 0.001,
and **** = p < 0.0001 compared to the corre-
sponding vehicle group. ## = p < 0.01 compared
to the DIZ cPTH group.mice were generated by crossing C57BL/6 GaS fl/fl mice with C57BL/6 CD4-
Cre mice. All mice were maintained under specific pathogen free conditions
and fed sterilized food and autoclaved water ad libitum.
In Vivo cPTH Treatment
80 mg/kg/day of hPTH1-34 (Bachem California Inc.) or vehicle was infused for
2 weeks in 16-week-old female mice by implanting ALZET osmotic pump
model 1002 (DURECT Corporation) with a delivery rate of 0.24 ml/hr, as previ-
ously described (Gao et al., 2008; Tawfeek et al., 2010).
IL-17A Ab Treatment
Sixteen-week-old WT mice were infused with vehicle or PTH for 2 weeks.
These mice were also injected with mouse IL-17A neutralizing antibody (IL-
17A Ab) (R&D Systems, MAB421) or isotype-matched irrelevant Ab (Irr.Ig) at
2.5 mg/kg, twice per week.
Diltiazem Treatment
Sixteen-week-old WT mice were infused with vehicle or PTH for 2 weeks.
These mice received regular water or 100 mg/kg body weight/day diltiazem
(Enzo Life Sciences) with the drinking water.
T Cell Transfers
Splenic naive CD4+ cells (CD4+CD44loCD62Lhi) from IL-17A-eGFP mice were
FACS sorted. WT, TNF/, TNFR1/, and TNFR2/ spleen T cells were pu-
rified by negative immunoselection using MACS Pan T cell isolation kit (Milte-
nyi Biotech). These cells were injected (5 3 106 cells per mouse) i.v. into
TCRb/ recipient mice 2 weeks before treatment. Successful T cell engraft-Cell Metabolism 22, 799–810,ment was confirmed by flow cytometry of the
spleens of the recipient mice harvested at
sacrifice.
BrdU Incorporation
Mice were injected i.p. with 1 mg of BrdU solution
48 hr before sacrifice. The detection of BrdU incor-
poration for proliferating cells was performed by
using BrdU Flow Kit (BD Biosciences) and
analyzed by FACS. The percentage of IL-
17A+BrdU+ cells was quantified by gating IL-
17A+CD4+ T cells in CD3+ cells.
In Vivo and In Vitro Th17Cell Differentiation
Sorted splenic naive (CD62LhiCD44low) CD4+
T cells from IL17A-GFP knockin mice
(IL17atm1Bcgen/J mice) were injected i.v. into 14-
week-old TCRb/ mice (2 3 106 per mouse).
Host mice were treated with vehicle or cPTH for
2 weeks starting 2 weeks after the adoptive
transfer of T cells. Mice were then sacrificed andspleen and BM cells were harvested and incubated with phorbol 12-myristate
13-acetate (50 ng/ml, Sigma) and ionomycin (1 mg/ml, Sigma) in the presence
of GolgiStop (1 mg/ml, Biolegend) for 4 hr. The cells were further stained with
surface marker and analyzed for GFP expression. For in vitro studies, naive
CD4+ T cells frommice treatedwith vehicle or cPTH for 2weekswere activated
with plate-bound anti-CD3 (2 mg/ml) and anti-CD28 (2 mg/ml) in the presence
of TNF (10–50 ng/ml) for 3 days. Cells were then harvested for FACS analysis
of CD4+IL-17A+ cells.
IL-17A ELISA
CD4+ T cells were purified using CD4-specific MACS Microbeads (Miltenyi
Biotec) following the manufacturer’s instructions. Cells were cultured for
48 hr with 1 mg/ml anti-CD28 (Biolegend) on anti-CD3-coated plates. Superna-
tants were collected and assayed for IL-17 by ELISA kit (R&D Systems) ac-
cording to the manufacturer’s directions.
mCT Measurements
mCT scanning and analysis was performed as reported previously (Tawfeek
et al., 2010; Terauchi et al., 2009) using a Scanco mCT-40 scanner. Additional
information is provided as Supplemental Information.
Quantitative Bone Histomorphometry
The measurements, terminology, and units used for histomorphometric anal-
ysis were those recommended by the Nomenclature Committee of the
American Society of Bone and Mineral Research (Dempster et al., 2013).
Non-consecutive longitudinal sections of the femur were prepared and
analyzed as described previously (Robinson et al., 2015). Additional informa-
tion is provided as Supplemental Information.November 3, 2015 ª2015 Elsevier Inc. 807
Osteoblast and Dendritic Cell Purification
BM cells were collected at sacrifice, and OBs were purified as previously
described (Bedi et al., 2012; Gao et al., 2008). Additional information is pro-
vided as Supplemental Information.
RNA Isolation from Enriched Osteocytes
The distal end of a tibia was cut off and BM cells were removed by centri-
fuging at 12,000 rpm for 2 min. The surfaces of the bone shafts were scraped
to remove the periosteum, and the bone was cut into a few small pieces.
Bone pieces were then digested with 1 ml of Hank’s solution containing
0.1% bovine serum albumin, 1 mM CaCl2, and 1 mg/ml collagenase (type
I:II, ratio 1:3) in a 12-well plate. A total of six digestions for 15 min were per-
formed at 37C on a rocking platform at 90 oscillations per minute to remove
the cells on the bone surface. After the final digestion, bone pieces were
washed with PBS and frozen in liquid nitrogen. For RNA isolation, bone
pieces were transferred into a tube of 1 ml TRIzol reagent with five stainless
steel beads and the sample was spun in a refrigerated bullet blender centri-
fuge at 12,000 rpm for 10 min. The supernatant was transferred into a new
tube, and RNA was extracted.
Markers of Bone Turnover
Serum CTX, P1NP and osteocalcin were measured by rodent-specific ELISA
assays (Immunodiagnostic Systems).
Flow Cytometry and Cell Sorting
For surface staining, cells were stained with anti-mouse CD3, CD4, CD62L,
and CD44 antibodies (Biolegend). For intracellular staining, cells were incu-
bated with phorbol 12-myristate 13-acetate (50 ng/ml, Sigma) and ionomycin
(1 mg/ml, Sigma) in the presence of GolgiStop (1 mg/ml, Biolegend) at 37C for
4 hr. Cells were then stained with anti-mouse CD3 and CD4 antibodies fol-
lowed by intracellular staining with anti-mouse IL-17A, IFNg, IL-4, and Foxp3
antibodies (Biolegend). Cells were then subjected to FACS analysis on an
LSRII (BD Biosciences) and analyzed using FlowJo software (TreeStar).
Real-Time RT-PCR and Murine Primers
The expression levels of murine IL-17A, RORa, RORgt, IL-21, IL-23, IL-23R,
TNFR1, TRAF2, IL-1b, IL-6, RANKL, and TNFa mRNA levels were quantified
by real-time RT-PCR. Murine RNAs levels were measured in BM and spleen
CD4+ cells, as well as unfractionated nucleated peripheral blood cells. All
the primers used were designed by Primer Express Software v2.0 (PE Bio-
systems). Changes in relative gene expression between vehicle and cPTH
groups were calculated using the 2DDCT method with normalization to 18S
rRNA. The primers used are provided in Supplemental Experimental
Procedures.
Statistical Analysis
Human cytokines and RORC mRNA levels and serum Ca, PTH, and 25OH
vitamin D levels were analyzed by Mann-Whitney (healthy controls versus
PHPT before surgery and healthy controls versus PHPT after surgery) and
Wilcoxon matched-pairs signed-rank tests (PHPT versus PHPT after sur-
gery), as the data were not normally distributed according to the Shapiro-
Wilk normality test. Serum levels of phosphorous and the demographic
data were analyzed by one-way ANOVA, as these data were normally distrib-
uted. To evaluate the effects of age and gender on IL-17A and RORC levels,
multivariate general linear regression models (GLMs) on logarithmic scale
were fitted for age, gender, and IL-17A or RORC mRNA levels at baseline
and their interactions. The relationship between serum PTH levels and IL-
17A and RORC mRNA levels were further analyzed by nonparametric
Spearman correlations.
Murine data were normally distributed according to the Shapiro-Wilk
normality test and analyzed by unpaired t tests or two-way ANOVA as appro-
priate. Additional information is provided as Supplemental Information.
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Supplemental Information includes Supplemental Experimental Procedures,
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